Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Jounce Therapeutics, Inc.
Study ID
NCT04319224
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vopratelimab — DRUG
    Specified dose on specified days
  • Ipilimumab — DRUG
    Specified dose on specified days
  • Nivolumab — DRUG
    Specified dose on specified days

Study Details

JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies who have previously participated in a vopratelimab study (the parent study).

Key Dates

First listed
Mar 24, 2020
Start date
Mar 10, 2020
Status verified
May 2024
Primary completion
Jan 3, 2023
Completion
Jan 3, 2023

Study Design

Enrollment
4 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vopratelimab
    Participants will continue to receive vopratelimab monotherapy per parent protocol.
  • Experimental: Vopratelimab with ipilimumab
    Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.
  • Experimental: Vopratelimab with nivolumab
    Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.

Primary Outcome Measure

Percentage of Subjects With Adverse Events (AEs) [ Time Frame: Approximately 34 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110-
The University of Texas - MD Anderson Cancer CenterHoustonTexas77030-
University of Virginia Health SystemsCharlottesvilleVirginia22908-

Find similar trials in St Louis, MO

By research site
Washington University School of Medicine· St Louis, MOThe University of Texas - MD Anderson Cancer Center· Houston, TXUniversity of Virginia Health Systems· Charlottesville, VA

Related Studies